Trials / Completed
CompletedNCT00169533
Rollover Study Of Lapatinib In Cancer Patients
An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is available pending FDA approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW572016 oral tablets | Lapatinib either at 750, 1000, 1250 or 1500 mgs |
Timeline
- Start date
- 2004-08-19
- Primary completion
- 2009-05-05
- Completion
- 2009-05-05
- First posted
- 2005-09-15
- Last updated
- 2017-11-17
Locations
12 sites across 3 countries: United States, Canada, Israel
Source: ClinicalTrials.gov record NCT00169533. Inclusion in this directory is not an endorsement.